Synthesis and anti-HIV activity of (-)-β-d-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-β-d-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs

Antiviral Research

Volumn 75, Issue 3, 2007, Pages 198-209

  Narayanasamy, Janarthanan ^a   Pullagurla, Manik R ^a   Sharon, Ashoke ^a   Wang, Jianing ^a   Schinazi, Raymond F ^b   Chu, Chung K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amdoxovir; Anti HIV activity; DAPD; Dioxolane 2,6 diaminopurine; Dioxolane guanine; Nucleoside; Prodrug

Indexed keywords

2 AMINO 3 METHYLBUTYRIC ACID 4 (2,6 DIAMINOPURIN 9 YL)[1,3]DIOXALAN 2 YLMETHYL ESTER; 2 AMINO 3 METHYLBUTYRIC ACID 4 (2,6 DIAMINOPURIN 9 YL)[1,3]DIOXOLAN 2 YLMETHYL ESTER; 2 TERT BUTOXYCARBONYLAMINO 3 METHYLBUTYRIC ACID 4 (2,6 DIAMINOPURIN 9 YL)[1,3]DIOXOLAN 2 YLMETHYL ESTER; [4 (2,6 DIAMINOPURIN 9 YL)[1,3]DIOXALAN 2 YL]METHANOL; [4 (2,6 DIAMINOPURIN 9 YL)[1,3]DIOXALAN 2 YL]METHANOL CITRATE; [4 (2,6 DIAMINOPURIN 9 YL)[1,3]DIOXALAN 2 YL]METHANOL MALEATE; [4 (2,6 DIAMINOPURIN 9 YL)[1,3]DIOXOLAN 2 YL]METHANOL TARTRATE; AMDOXOVIR; BETA DEXTRO 1,3 DIOXOLAN 2 AMINO 6 AMINOETHYLPURINE; BETA DEXTRO 2 AMINO 6 AZIDO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL)PURINE; BETA DEXTRO 2 AMINO 6 CHLORO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL)PURINE; BETA DEXTRO 2 AMINO 6 CYCLOPROPYLAMINO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 Y)PURINE; BETA DEXTRO 2 AMINO 6 CYCLOPROPYLAMINO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL)PURINE; BETA DEXTRO 2 AMINO 6 DIMETHYLAMINO 9 (2 HYDROXYLMETHYL 1,3 DIOXALAN 4 YL)PURINE; BETA DEXTRO 2 AMINO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL) 6 BENZYLAMINOPURINE; BETA DEXTRO 2 AMINO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL) 6 CYCLOBUTYLAMINOPURINE; BETA DEXTRO 2 AMINO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL) 6 ISOPROPYLAMINOPURINE; BETA DEXTRO 2 AMINO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL) 6 METHOXYPURINE; BETA DEXTRO 2 AMINO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL) 6 METHYLAMINOPURINE; BETA DEXTRO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL) N 1 METHYLGUANOSINE; BETA DEXTRO 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL)GUANOSINE; BETA DEXTRO N 1 BENZYL 9 (2 HYDROXYLMETHYL 1,3 DIOXALAN 4 YL)GUANOSINE; BETA DEXTRO N 1 BENZYL 9 (2 HYDROXYMETHYL 1,3 DIOXALAN 4 YL)GUANOSINE; CARBOXYLIC ACID; GUANOSINE DERIVATIVE; ISOBUTYRIC ACID 4 (2 AMINO 6 CHLOROPURIN 9 YL)[1,3]DIOXOLAN 2 YLMETHYL ESTER; ISOBUTYRIC ACID 4 ACETOXY[1,3]DIOXOLAN 2 YLMETHYL ESTER; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VERO CELL;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; DIOXOLANES; DRUG STABILITY; GUANOSINE; HIV; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; PRODRUGS; PURINE NUCLEOSIDES; SOLUBILITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34250218925     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.03.005     Document Type: Article

References (51)

1. Badet B., Julia M., and Lefebvre C. The efficiency of diphenylsulfonium salts as alkylating agents. Bull. Soc. Chim. Fr. 11 (1984) 431-434
2. Baer H.P., Drummond G.I., and Gillis J. Studies on the specificity and mechanism of action of adenosine deaminase. Arch. Biochem. Biophys. 123 (1968) 172-178
3. Balzarini J. Metabolism and mechanism of antiviral action of purine and pyrimidine derivatives. Pharm. World Sci. 16 (1994) 113-126
4. Barchi J.J., Marquez V.E., Driscoll J.S., Ford H., Mitsuya H., Shirasaka T., Aoki S., and Kelley J.A. Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs. J. Med. Chem. 34 (1991) 1647-1655
5. Bazmi H.Z., Hammond J.L., Cavalcanti S.C.H., Chu C.K., Schinazi R.F., and Mellors J.W. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-d-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 44 (2000) 1783-1788
6. Benzaria S., Pierra C., Bardiot D., Cretton-Scott E., Bridges E.G., Zhou X.-J., Standring D., and Gosselin G. Monoval-ldC: efficient prodrug of 2′-deoxy-beta-l-cytidine (l-dC), a potent and selective anti-HBV agent. Nucleosides, Nucleotides Nucleic Acids 22 (2003) 1003-1006
7. Biron K.K., De Miranda P., Burnette T.C., and Krenitsky T.A. Selective anabolism of 6-methoxypurine arabinoside in varicella-zoster-infected cells. Antimicrob. Agents Chemother. 35 (1991) 2116-2120
8. Chassy B.M., and Suhadolink R.J. Adenosine aminohydrolase, binding and hydrolysis of 2 and 6-substituted ribonucleosides and 9-substituted adenine nucleosides. J. Biol. Chem. 242 (1967) 3655-3658
9. Chen H., Schinazi R.F., Rajagopalan P., Chu C.K., McClure H.M., and Boudinot F.D. Pharmacokinetics of (-)-beta-d-dioxolane guanine and prodrug (-)-beta-d-2,6-diaminopurine dioxolane in rats and monkeys. AIDS Res. Human Retrovir. 15 (1999) 1625-1630
10. Chong Y., Borroto-Esoda K., Furman P.A., and Schinazi R.F. Molecular mechanism of DAPD/DXG against zidovudine- and lamivudine-drug resistant mutants: a molecular modelling approach. Antivir. Chem. Chemother. 13 (2002) 115-128
11. Chong Y., and Chu C.K. Molecular mechanism of dioxolane nucleoside against 3TC resistant M184V HIV mutant. Antiviral. Res. 63 (2004) 7-13
12. Chu C.K., Ahn S.K., Kim H.O., Beach J.W., Alves A.J., Jeong L.S., Islam Q., Roey P.V., and Schinazi R.F. Asymmetric synthesis of enantiomerically pure (-) (1R, 4R)-dioxolane thymine and its anti-HIV activity. Tetrahedron Lett. 32 (1991) 3791-3794
13. Chu C.K., Yadav V., Chong Y., and Schinazi R.F. Anti-HIV activity of (-)-(2R, 4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism. J. Med. Chem. 48 (2005) 3949-3952
14. Chu C.K., Beach J.W., Jeong L.S., Choi B.G., Comer F.I., Alves A.J., and Schinazi R.F. Enantiomeric synthesis of (+) BCH-189 [(+)-(2S,5R)-1-[2-(hydroxymethyl))-1,3-oxathiolan-5-yl]cytosine] from d-manose and its anti-HIV activity. J. Org. Chem. 56 (1991) 6503-6505
15. Chulay J., Biron K., Wang L., Underwood M., Chamberlain S., Frick L., Good S., Davis M., Harvey R., Townsend L., Drach J., and Koszalka G. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Adv. Exp. Med. Biol. 458 (1999) 129-134
16. Corey J.G., and Suhadolnik R.J. Structural requirements of nucleosides for binding adenosine deaminase. Biochemistry 4 (1966) 1729-1732 1733-1735
17. Daluge S.M., Good S.S., Falettto M.B., Miller W.H., St Clair M.H., Boone L.R., Tisdale M., Parry N.R., and Reardon J.E. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41 (1997) 1082-1093
18. Deeks S., Kessler H., Eron J., Thompson M., Raffi F., Jacobson J., Sista N., Bigley J., and Rousseau F. Proceedings of the 4th International Workshop on HIV Drug Resistance & Treatment Strategies. Sitges, Spain (2000) (abstract 5)
19. De Clercq E. Antiviral drugs: current state of the art. J. Clin. Virol. 22 (2001) 73-83
20. Fleisher D., Bong R., and Stewart B.H. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv. Drug Deliv. Rev. 19 (1996) 115-130
21. Frederiksen S. Specificity of adenosine deaminase toward adenosine and 2′-deoxyadenosine analogues. Arch. Biochem. Biophys. 113 (1996) 383-388
22. Furman P.A., Jeffrey J., Kiefer L.L., Feng J.Y., Anderson K.S., Borroto-Esoda K., Hill E., Copeland W.C., Chu C.K., Sommadossi J.-P., Liberman I., Schinazi R.F., and Painter G.F. Mechanism of action of 1-β-d-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-β-d-dioxolane guanosine. Antimicrob. Agents Chemother. 45 (2001) 158-165
23. Gallant J.E., Gerondelis P.Z., Wainberg M.A., Shulman N.S., Haubrich R.H., and St. Clair M. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther. 8 (2003) 489-506
24. Ghosh M., and Miller M. Design, synthesis and biological evaluation of isocyanurate-based antifungal and macrolide antibiotic conjucates-iron transport-mediated drug delivery. Bioorg. Med. Chem. 3 (1995) 1519-1525
25. Glynis D. Changing the salt, changing the drug. Pharm. J. 266 (2001) 322-323
26. Gu Z., Wainberg M.A., Nguyen-Ba P., L'Heureux L., de Muys J.M., and Rando R.F. Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine nucleosides. Nucleotides Nucleic Acids 18 (1999) 891-892
27. Gu Z., Wainberg M.A., Nguyen-Ba P., L'Heureux L., de Muys J.M., Bowlin T.L., and Rando R.F. Mechanism of action and in vitro activity of 1′, 3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob. Agents Chemother. 43 (1999) 2376-2382
28. Han H.K., and Amidon G.L. Targeted prodrug design to optimize drug delivery. AAPS Pharmsci. 2 (2000) Art.no.6
29. Kennedy T. Managing the drug discovery/development interface. Drug Discov. Today 2 (1997) 436-444
30. Kim H.O., Ahn S.K., Alves A.J., Beach J.W., Jeong L.S., Choi Bo.G., Roey P.V., Schinazi R.F., and Chu C.K. Asymmetric synthesis of 1,3-dioxalane-pyrimidine nucleosides and their anti-HIV activity. J. Med. Chem. 35 (1992) 1987-1995
31. Kim H.O., Schinazi R.F., Nampalli S., Shanmuganathan K., Cannon D.L., Alves A.J., Jeong L.S., Beach J.W., and Chu C.K. 1,3-Dioxolanyl purine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. J. Med. Chem. 36 (1993) 30-37
32. Kim H.O., Schinazi R.F., Nampalli S., Shanmuganathan K., Jeong L.S., Beach J.W., Nampalli S., Cannon D.L., and Chu C.K. l-β-(2S,4S) and l-α-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. J. Med. Chem. 36 (1993) 519-528
33. Lalezari J.P., Aberg J.A., Wang L.H., Wire M.B., Richard Miner R., Snowden W., Talarico C.L., Shaw S., Jacobson M.A., and Drew W.L. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46 (2002) 2969-2976
34. Liang Y., Narayanasamy J., Schinazi R.F., and Chu C.K. 2006 Phosporamidate and phosphate prodrugs of (-)-β-d-(2R,4R)-dioxolane-tymine: synthesis, anti-HIV activity and stability studies. Bioorg. Med. Chem. 14 (2006) 2178-2189
35. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellman N., and Richman D.D. Antiretroviral-drugresistance among patients recently infected with HIV. N. Engl J. Med. 347 (2002) 385-394
36. Margolis D., Mukherjee L., Hogg E., Fletcher C., Ogata-Arakaki D., Petersen T., Rusin D., Martinez A., Adams E., Mellors J., and Adult AIDS Clinical Trials Group A5165 Team. DAPD, NRTI-modestly reduced viral load & no safety issues. Proceedings of the 13th CROI (Conference on Retroviruses and Opportunistic Infections. Denver, Colorado, February 5-8 (2006)
37. Marquez V.E., Tseng C.K.-H., Mitsuya H., Aoki S., Kelley J.A., Ford H., Roth J.S., Broder S., Johns D.G., and Driscoll J.S. Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV. J. Med. Chem. 33 (1990) 978-985
38. Mocroft A., Phillips A.N., Friis-Moller N., Colebunders R., Johnson A.M., Hirschel B., Saint-Marc J.D., Staub T., Clotet B., and Lundgren J.D. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir. Ther. 7 (2002) 21-30
39. Pauwels R., Baba M., Balzarini J., Herdewijin P., Desmyther J., Robins M.J., Zou R., Madej D., and De Clercq E. Investigations on the anti-HIV activity of 2′,3′-dideoxyadenosine analogues with modifications in either the pentose or purine moiety. Biochem. Pharmacol. 37 (1988) 1317-1325
40. Robins M.J., and Basom G.L. Nucleicacid related compounds: direct conversion of 2′-deoxyinosine to 6-chloropurine 2′-deoxyriboside and selected 6-substituted deoxynucleosides and their evaluation as substrates of adenosine deaminase. Can. J. Chem. 51 (1973) 3161-3169
41. Schinazi R.F., Sommadossi J.P., Saalmann V., Cannon D.L., Xie M.-W., Hart G.C., Smith G.A., and Hahn E.F. Activity of 3′-azido-3′-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 34 (1990) 1061-1067
42. Schinazi R.F., Cannon D.L., Arnold B.H., and Martino-Saltzman D. Combinations of isoprinosine and 3′-azido-3′-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 32 (1998) 1784-1787
43. Shirasaka T., Murakami K., Ford H., Kelley J.A., Yoshioka H., Kojima E., Aoki S., Broder S., and Mitsuya H. Lipophilic halogenated congeners of 2′,3′-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 9426-9430
44. Song X., Vig B.S., Lorenzi P.L., Drach J.C., Townsend L.B., and Amidon G.L. Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-d-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter. J. Med. Chem. 48 (2005) 1274-1277
45. Stuyver L.J., Lostia S., Admas M., Mathew J., Pai B.S., Grier J., Tharnish P., Choi Y., Chong Y., Choo H., Chu C.K., Otto M.J., and Schinazi R.F. Antiviral activities and cellulose toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents Chemother. 46 (2002) 3854-3960
46. Tamalet C., Fantini J., Tourres C., and Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 17 (2003) 2383-2388
47. Thompson M.A., Kessler H.A., Eron Jr. J.J., Jacobson J.M., Adda N., Shen G., Zong J., Harris J., Moxham C., Rousseau F.S., and DAPD 101 Study Group. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS 19 (2005) 1607-1615
48. Turner D., Brenner B., and Wainberg M.A. Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1. J. Antimicrob. Chemother. 53 (2004) 53-57
49. Vince R., and Hua M. Synthesis and anti-HIV activity of carbocyclic 2′,3′-didehydro-2′,3′-dideoxy 2,6-disubstituted purine nucleosides. J. Med. Chem. 33 (1990) 17-21
50. Walmsley S. Individualized therapy for the treatment-experienced patient. AIDS Read. 13 6 Suppl (2003) S11-S15
51. Ye S., Rezende M.M., Deng W.P., Herbert B., Daly J.W., Roger J.A., and Kirk K.L. Synthesis of 2′,5′-dideoxy-2′,5′-difluoroadenosine: Potent P-site inhibitors of adenyl cyclase. J. Med. Chem. 47 (2004) 1207-1213